EGFR and non-small cell lung carcinoma: Although osimertinib is effective in most NSCLC patients with the EGFR-T790M mutation, a 71% objective response rate and 10.1 months median PFS were recorded in a clinical trial; however, the mechanisms underlying patient response to osimertinib treatment are still unclear [6].